Affirmation of Primary prevention with Pravastatin in Reduction of Occlusive Atherosclerotic Complications in Hypercholesterolemia -Japan study
Not Applicable
- Conditions
- Hypercholesterolemia
- Registration Number
- JPRN-jRCT1080220524
- Lead Sponsor
- DAIICHI SANKYO COMPANY, LIMITED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 5000
Inclusion Criteria
Hypercholesterolemia, under a Mevalotin treatment, outpatient, consenting patient, 2-years follow-up available, men aging >= 20, women aging >= 55 or after menopause, defined as a high risk group on primary prevention by JAS guideline 2007.
Exclusion Criteria
A history of cardiovascular diseases (myocardial infarction, unstable angina, stroke (excluding TIA), CABG/PCI, arteriosclerosis obliterans) before registration.
A diagnosis severe arrhythmia, familial hypercholesterolemia, uncontrolled hypertension or diabetes mellitus, severe liver or renal disease, current diagnosis of severe disease (ex. malignancy), contraindicated to pravastatin.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method